Etanercept biosimilar SB4 in the treatment of plaque-type psoriasis and psoriatic arthritis: a single-center, observational, retrospective, real-life study

The approval of the etanercept biosimilar SB4 (Brenzys, Benepali; Samsung Bioepis Co., Ltd.) for psoriasis and psoriatic arthritis (PsA) was automatically obtained on the basis of the demonstration of quality, biological activity, efficacy, safety, and immunogenicity similarity to the reference etanercept in the treatment of rheumatoid arthritis (1, 2). Being the development of biosimilars a significant opportunity to decrease medical care cost and increase treatment options (3), extrapolation of clinical data from other indications determined an intense scientific debate on the interchangeability between originator and biosimilar in real-life, and recently reports on efficacy and safety of the biosimilar SB4 in plaque-type psoriasis have been published (4, 5). The aim of our observational, retrospective, single-center, study was to investigate the etanercept biosimilar SB4 in patients affected by plaque-type psoriasis and PsA. This article is protected by copyright. All rights reserved